SEHK:1378
SEHK:1378Metals and Mining

Taking Stock of China Hongqiao Group (SEHK:1378) After Its Inclusion in the Hang Seng China Enterprises Index

China Hongqiao Group Added to a Key Benchmark China Hongqiao Group (SEHK:1378) just joined the Hang Seng China Enterprises Index. This shift can pull in institutional money and passive index tracking capital, subtly reshaping the stock’s demand dynamics. See our latest analysis for China Hongqiao Group. The inclusion comes after a powerful run, with the latest share price at HK$31.7 and a year to date share price return of 178.56%, backed by a 1 year total shareholder return of 193.30% that...
SEHK:700
SEHK:700Interactive Media and Services

Tencent (SEHK:700) Valuation Check After Gaming Surge and Nvidia Cloud Workaround Boost Growth Prospects

Tencent Holdings (SEHK:700) is back in focus after China’s video game industry hit a new revenue high, while the company quietly tapped Japanese cloud partners to access Nvidia Blackwell chips despite ongoing US export controls. See our latest analysis for Tencent Holdings. Those themes are already feeding into sentiment, with the share price up strongly on a year to date basis and a solid one year total shareholder return suggesting momentum is still broadly constructive rather than...
SEHK:2005
SEHK:2005Pharmaceuticals

New NMPA Drug Approvals Might Change The Case For Investing In SSY Group (SEHK:2005)

Earlier in December 2025, SSY Group announced that it had received NMPA approval in China to produce and register Levofloxacin Eye Drops and Compound Sodium Picosulfate Granules, both classified as having passed consistency evaluation. These approvals deepen SSY Group’s ophthalmic and gastrointestinal product lineup, potentially strengthening its position in specialist hospital and pre-procedure medication markets. We’ll now examine how the NMPA approvals, particularly the Levofloxacin Eye...
SEHK:6682
SEHK:6682Software

Evaluating Beijing Fourth Paradigm Technology (SEHK:6682)’s Valuation After Governance and Board Reforms

Beijing Fourth Paradigm Technology (SEHK:6682) just pushed through a package of governance changes at its December meetings, revising its Articles, refreshing its English name, and adding independent director Pan Jialin to the board. See our latest analysis for Beijing Fourth Paradigm Technology. These governance moves come after a tough stretch, with the latest HK$42.74 quote sitting against a 90 day share price return of minus 34.45% and a 1 year total shareholder return of minus 17.49%...
SEHK:916
SEHK:916Renewable Energy

Surging PV Output and Higher November Generation Might Change The Case For Investing In China Longyuan Power (SEHK:916)

China Longyuan Power Group Corporation Limited reported that its consolidated power generation for November 2025 rose 14.34% year on year to 6,944,492 MWh, with wind output higher and PV output growing very rapidly, and year-to-date 2025 generation edging 0.41% above the same period in 2024. An interesting takeaway is that, excluding coal power, the company’s 2025 output increased 12.07% year on year, driven by a 72.42% surge in PV generation and solid growth in wind. We will now look at how...
SEHK:293
SEHK:293Airlines

Cathay Pacific (SEHK:293) Valuation Check After Strong 1-Year Share Price Rebound

Cathay Pacific Airways (SEHK:293) has quietly rewarded patient investors, with the share price climbing around 37% over the past year and nearly doubling over five years as travel demand normalizes. See our latest analysis for Cathay Pacific Airways. That momentum is still very much alive, with a 90 day share price return of about 13.5% and a 1 year total shareholder return above 37%. This suggests confidence in the airline recovery story is building rather than fading. If Cathay’s rebound...
SEHK:2696
SEHK:2696Biotechs

Shanghai Henlius Biotech (SEHK:2696) Valuation Check After US FDA IND Approval for HLX18 Biosimilar Trial

Shanghai Henlius Biotech (SEHK:2696) just cleared a key hurdle by securing US FDA approval of its IND for HLX18, a nivolumab biosimilar, which paves the way for phase 1 trials in multiple solid tumors. See our latest analysis for Shanghai Henlius Biotech. That HLX18 milestone lands after a busy year for Henlius, with HLX22 plus HLX87 also moving deeper into breast cancer trials. It comes despite a 90 day share price return of minus 19.39 percent and a still eye catching three year total...
SEHK:2616
SEHK:2616Biotechs

GAVRETO’s NRDL Inclusion And China Alliance Network Might Change The Case For Investing In CStone Pharmaceuticals (SEHK:2616)

CStone Pharmaceuticals announced on 8 December 2025 that its targeted therapy GAVRETO (pralsetinib, 100 mg) has been included in China’s latest National Reimbursement Drug List, which will take effect on 1 January 2026 and broaden reimbursed access for RET-altered lung and thyroid cancer patients. The NRDL inclusion, combined with CStone’s existing commercialization partnership with Shanghai Allist in Mainland China, underscores how alliance-driven distribution is central to expanding...
SEHK:136
SEHK:136Entertainment

Assessing China Ruyi Holdings (SEHK:136) Valuation After Its HK$2.21b Follow-On Share Offering

China Ruyi Holdings (SEHK:136) just wrapped up a HK$2.21 billion follow on share sale via a subsequent direct listing, a material move that reshapes its capital base and raises fresh funds for expansion. See our latest analysis for China Ruyi Holdings. The follow on deal lands after a volatile stretch, with the latest HK$2.27 quote sitting below recent levels. The 90 day share price return of negative 21.72 percent contrasts with a still positive three year total shareholder return of 26.82...